| 发明名称 |
MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) |
| 摘要 |
The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells. |
| 申请公布号 |
US2016115485(A1) |
申请公布日期 |
2016.04.28 |
| 申请号 |
US201514963319 |
申请日期 |
2015.12.09 |
| 申请人 |
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. |
发明人 |
SAFADI Rifaat |
| 分类号 |
C12N15/113 |
主分类号 |
C12N15/113 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating and/or attenuating liver cancer in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of an agent capable of specifically inhibiting expression of a human NLGn4 gene product, said human NLGn4 gene product comprising SEQ ID NO: 2, thereby treating and/or attenuating the liver cancer. |
| 地址 |
Jerusalem IL |
